What question did this study set out to answer?

The research aims to evaluate the mechanistic effects of tozorakimab on pathways related to airway inflammation and tissue dysfunction in COPD patients.

May 20, 2026American Journal of Respiratory and Critical Care Medicine

B15-06 Tozorakimab, an Anti-IL-33 Antibody, Modulates Pathways Associated With Airway Inflammation and Tissue Dysfunction in COPD Patients: Mechanistic Evidence From FRONTIER-4

View Full Paper

Ask AI

Bookmark

Authors

MRM RytelewskiAstraZeneca (Finland)GPG De PaloAstraZeneca (Finland)MCM CardnerAstraZeneca (Finland)

Discussion

Member takes

Implication

Randomized trial assesses the effect of tozorakimab on airway inflammation in COPD patients, suggesting broader implications for treatment.

Key Points

The research aims to evaluate the mechanistic effects of tozorakimab on pathways related to airway inflammation and tissue dysfunction in COPD patients.
Collected spontaneous sputum and serum samples from COPD patients in FRONTIER-4 at baseline, weeks 4, 12, and 28 after administering tozorakimab or placebo.
Analyzed samples using the Olink Explore HT proteomic platform to assess changes in biomarker concentrations.
Radomized trial with a dosing regimen of tozorakimab 600 mg subcutaneously every 4 weeks.
Tozorakimab reduced lymphotoxin beta (LTB) concentration by 19.1% at week 12 (unadjusted p=0.018) and 29.3% at week 28 (unadjusted p=0.001).
It also reduced proteoglycan 3 (PRG3) by 47.1% at week 12 (unadjusted p=0.039) and 65.7% at week 28 (unadjusted p=0.004).
Numerical reductions in biomarkers of eosinophilic inflammation and neutrophil activation were observed across all time points.

Cite This Study

Rytelewski et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4f62f03e14405aa9aa88 https://doi.org/10.1093/ajrccm/aamag162.1751

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial assesses the effect of tozorakimab on airway inflammation in COPD patients, suggesting broader implications for treatment.

B15-06 Tozorakimab, an Anti-IL-33 Antibody, Modulates Pathways Associated With Airway Inflammation and Tissue Dysfunction in COPD Patients: Mechanistic Evidence From FRONTIER-4

Discussion

Member takes

Implication

Key Points

Cite This Study

B15-06 Tozorakimab, an Anti-IL-33 Antibody, Modulates Pathways Associated With Airway Inflammation and Tissue Dysfunction in COPD Patients: Mechanistic Evidence From FRONTIER-4

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider